CVRx’s Hypertension Implant Gains FDA Humanitarian Exemption

The humanitarian device exemption for the Barostim neo legacy implantable electronic stimulator for hypertension is CVRx’ first commercial approval in the U.S. The Minneapolis company is also developing the Barostim therapy for treatment of heart failure

More from Archive

More from Medtech Insight